综合生物信息学分析被用来识别和验证在结肠癌向治疗中差异表达的基因
Jialin Zhang1, Xinyu Wang1, Zhen Li1
1Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Research Center of Clinical Laboratory Science, School of Laboratory Medicine, Bengbu Medical University, Bengbu, 233030, Anhui, People's Republic of China.
Scientific reports
|April 28, 2025
概括
在结直肠癌 (CRC) 中,CLCA1和ZG16的低表达与预后不佳相关. 这些基因可以作为诊断生物标志物和CRC的免疫治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 大肠直肠癌 (CRC) 是一种普遍存在的恶性瘤.
- 在CRC中,CLCA1和ZG16被确定为潜在的下调基因.
研究的目的:
- 研究CLCA1和ZG16作为结直肠癌进展的预后生物标志物.
- 确定CLCA1和ZG16在CRC细胞行为中的作用及其与患者结果的关联.
主要方法:
- 使用GSE39582和TCGA数据集进行差异基因表达分析.
- 生物信息分析包括Venn图,GO,KEGG,GSEA和PPI网络.
- 定量实时PCR (qRT-PCR),CCK-8,划痕,克隆形成和Transwell测试用于功能验证.
主要成果:
- 与正常组织相比,CRC组织中的CLCA1和ZG16表达显着较低.
- 低CLCA1和ZG16的表达与糟糕的生存结果有关,并被确定为CRC预后的独立风险因素.
- 过度表达CLCA1和ZG16抑制了CRC细胞的增殖,迁移和入侵.
- 与CLCA1和ZG16相关的基因与GnRH信号通路有关.
结论:
- 在CRC中,CLCA1和ZG16显著下调,并与预后不佳有关.
- CLCA1和ZG16显示出CRC的诊断和预后生物标志物的潜力.
- CLCA1和ZG16可能是结直肠癌免疫治疗的新疗法标.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:07Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K